Disseminated peritoneal hydatidosis following blunt abdominal trauma: A case report

A middle age lady presented with abdominal pain was diagnosed to have multiple peritoneal and hepatic hydatid cysts on CT scan. Retrospectively she was found to have suffered blunt abdominal trauma

Is deep venous thrombosis a common complication in patients treated with Ilizarov external fixator?

Background: Determining the incidence of deep venous thrombosis (DVT), a prospective study, in patients treated with Ilizarov external fixators for lower extremity fractures, fracture non unions or deformity correction.Methods: A Prospective, observational and cross sectional study. 49 Patients with complex lower extremity injuries, deformities and non-union of fractures were treated with Ilizarov external fixator application, were assessed clinically and radiological (Venous Doppler) at regular intervals- 6 days post-surgery then at 6 weeks, 12 weeks and between 4 to 6 months post-operative. None were given chemoprophylaxis for the prevention of DVT and everyone were assessed pre operatively with a questionnaire and wells criteria was taken for assessment of high risk for developing venous thrombosis. There were 41 men and 8 women, 85.75% of the study group is of age 30 to 60 years.Results: Only 1 of 49 patients developed radiological evident DVT within 6 days of surgery. Patients who underwent application of Ilizarov external fixator electively for deformity correction, osteomyelitis and non-union showed no clinical or radiological evident signs of DVT.Conclusions: The incidence of DVT and PTE is minimal when patients without chemoprophylaxis underwent lower limb Ilizarov external fixator application for acute trauma and electively for deformity correction, treatment of non-union and osteomyelitis. However further comparative and randomized studies need to be done to confirm our results

Active Implantable cardioverter-defibrillators in Continuous-flow Left Ventricular Assist Device Recipients

Introduction Implantable cardioverter-defibrillator (ICD) in patients with heart failure with reduced ejection fraction reduces mortality secondary to malignant arrhythmias. Whether end-stage heart failure (HF) with continuous-flow left ventricular assist device (cf-LVAD) derive similar benefits remains controversial. Methods We performed a systematic literature review and meta-analysis of all published studies that examined the association between active ICDs and survival in advanced HF patients with cfLVAD. We searched PubMed, Medline, Embase, Ovid, and Cochrane for studies reporting the association between ICD and all-cause mortality in advanced HF patients with cfLVAD. Mantel-Haenszel risk ratio (RR) random-effects model was used to summarize data. Results Ten studies (9 retrospective and one prospective) with a total of 7,091 patients met inclusion criteria. There was no difference in all-cause mortality (RR 0.84, 95% CI 0.65–1.10, p=0.20, I2 =62.40%), likelihood of survival to transplant (RR 1.07, 95% CI 0.98–1.17, p= 0.13, I2 =0%), RV failure (RR 0.74, 95% CI 0.44–1.25, p = 0.26, I2 =34%) between Active ICD and inactive/no ICD groups, respectively. Additionally, 27.5% received appropriate ICD shocks, while 9.5% received inappropriate ICD shocks. No significant difference was observed in terms of any complications between the two groups. Conclusions All-cause mortality, the likelihood of survival to transplant, and worsening RV failure were not significantly different between active ICD and inactive/no ICD in cf-LVAD recipients. A substantial number of patients received appropriate ICD shocks suggesting a high-arrhythmia burden. The risks and benefits of ICDs must be carefully considered in patients with cf-LVAD

DEPLOYR: A technical framework for deploying custom real-time machine learning models into the electronic medical record

Machine learning (ML) applications in healthcare are extensively researched, but successful translations to the bedside are scant. Healthcare institutions are establishing frameworks to govern and promote the implementation of accurate, actionable and reliable models that integrate with clinical workflow. Such governance frameworks require an accompanying technical framework to deploy models in a resource efficient manner. Here we present DEPLOYR, a technical framework for enabling real-time deployment and monitoring of researcher created clinical ML models into a widely used electronic medical record (EMR) system. We discuss core functionality and design decisions, including mechanisms to trigger inference based on actions within EMR software, modules that collect real-time data to make inferences, mechanisms that close-the-loop by displaying inferences back to end-users within their workflow, monitoring modules that track performance of deployed models over time, silent deployment capabilities, and mechanisms to prospectively evaluate a deployed model's impact. We demonstrate the use of DEPLOYR by silently deploying and prospectively evaluating twelve ML models triggered by clinician button-clicks in Stanford Health Care's production instance of Epic. Our study highlights the need and feasibility for such silent deployment, because prospectively measured performance varies from retrospective estimates. By describing DEPLOYR, we aim to inform ML deployment best practices and help bridge the model implementation gap

Detubularized isolated ureterosigmoidostomy in a complicated common cloaca: A case report

Urinary incontinence in a child secondary to a severe congenital anatomical disorder or due to complication of a previous surgery can be difficult to manage. Decisions can be especially hard when a redo procedure is being considered. We present one such case where a 6 year old girl previously operated for cloaca was brought with incontinence and after much consideration of options available, underwent a modified ureterosigmoidostomy to aid in her continence. The modification used was detubularized isolated ureterosigmoidostomy, described by Atta et al in 1996

An application of a rule-based system towards resolving exception events of business processes within a small Virtual Organization

The motivation behind this research work is explained first within the context of a European Union funded project called “SYNERGY”. A business scenario of a small virtual organization is presented to discuss what happens if exception events occur within the life cycle of a business scenario, and how they could be resolved to enable the business to operate successfully. To investigate these aspects, the paper briefly explores the role of events within the context of “Collaboration Moderator Services” which aim to increase awareness between collaborative partners during the workflow of a business scenario and then suggests a possible remedy through the use of a rule-based system. A description of a methodology adopted for creation and capture of knowledge needed to resolve the exception events, transform the captured knowledge into rule-sets and implement them in a commercial rule-based system – “XpertRule” is given. Screen shots of this implementation are provided in the paper. Based on this implementation, the paper then concludes with a discussion

Identifying Critical Roles for the Lamin B Receptor and Additional Nuclear Envelope Proteins in Regulating the Proliferation and Differentiation of Myeloid Progenitors

Neutrophils are blood phagocytes that contain lobulated nuclei, development of which depend on the expression of an inner nuclear membrane (INM) protein called the lamin B receptor (LBR). Loss of LBR expression causes not only hypolobulation of neutrophil nuclei (Pelger-Huët anomaly) but also severe developmental defects in humans (HEM/Greenberg dysplasia) and mice (ichthyosis). LBR is considered a dual function protein: the N-terminal domain contains chromatin and lamin B binding sites, whereas the C-terminal domain anchors LBR to the INM and exhibits C14 sterol reductase activity. Despite our knowledge of these two structural features of LBR, which domain supports normal development is unclear. We recently addressed this issue with regards to myelopoiesis by expressing wild-type and mutant forms of mouse Lbr in myeloid cells derived from an ichthyosis mouse. We demonstrated that expression of the Lbr sterol reductase domain alone can support nuclear morphologic maturation and is critical to both cholesterol biosynthesis and lipid-stressed proliferative responses of myeloid progenitors. In contrast, myeloid progenitors that lack the homologous C14 sterol reductase Tm7sf2 displayed normal nuclear maturation, cholesterol biosynthesis and lipid-stressed proliferation. We have now generated ichthyosis myeloid cells that express forms of Lbr with missense mutations in the sterol reductase domain known to cause HEM/Greenberg dysplasia. Our preliminary results indicate that these sterol reductase missense mutations disrupt cholesterol biosynthesis and lipid-stressed proliferation, but do not appear to affect nuclear maturation. We are also analyzing the expression patterns of Lbr and two additional nuclear envelope (NE) proteins, Lamin A/C and Sun2, during neutrophil vs. macrophage differentiation using both cell line models and ex vivo differentiated mouse bone marrow, and examining how overexpression of either Lamin A/C or Sun2 affects myeloid differentiation. Our studies may reveal new insight into how different NE proteins regulate the complex functions of two professional phagocytes

Preterm birth among pregnancies conceived by assisted reproduction techniques in Mumbai, Maharashtra, India

Background: Preterm births are an enormous global problem on families, medical system and economy. The rates of preterm birth are increasing and one of the contributors is growing use of Assisted Reproduction Techniques (ART) leading to multifetal gestations. Some risk factors for preterm birth are specific to women who conceive by ART. Since there is limited data from India, this pilot study was undertaken to assess the magnitude of preterm birth among pregnancies conceived by ART and to study the contributing factors.Methods: Clinic based descriptive cohort study through eight ART clinics in Mumbai for one year. Data was collected using an in-depth questionnaire on socio-demographic characteristics, medical history, ART details, course and complications during pregnancy, mode of delivery, pregnancy outcome, risk factors related to preterm birth and neonatal outcome. Complete details of 113 participants who completed the study were analyzed.Results: Study showed high incidence of preterm birth (76.23%) among women conceived with ART. Multiple gestations were observed in 45.1%. Pregnancy related complications like heterotrophic pregnancy (3%), pre eclampsia (15%) and gestational diabetes (11%) were high. Incidence of caesarean section was very high (98%). Neonatal outcome was good with 98% live births and only 2 still births.Conclusions: Present study highlights that preterm birth, multiple pregnancies, pregnancy related complications like preeclampsia, gestational diabetes and caesarean sections are very high among women conceived by ART. With growing use of ART there is an urgent need to develop a National ART Surveillance system in India like the one in Centre for Disease Control Atlanta to get complete data on the pregnancy course and outcomes of ART conceptions. Efforts to limit the number of embryos transferred should be strengthened to prevent multiple births

The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment

Abstract Background Rifampicin reduces the plasma concentrations of nevirapine in human immunodeficiency virus (HIV) and tuberculosis (TB) co-infected patients, who are administered these drugs concomitantly. We conducted a prospective interventional study to assess the efficacy of nevirapine-containing highly active antiretroviral treatment (HAART) when co-administered with rifampicin-containing antituberculosis treatment (ATT) and also measured plasma nevirapine concentrations in patients receiving such a nevirapine-containing HAART regimen. Methods 63 cases included antiretroviral treatment naïve HIV-TB co-infected patients with CD4 counts less than 200 cells/mm3 started on rifampicin-containing ATT followed by nevirapine-containing HAART. In control group we included 51 HIV patients without tuberculosis and on nevirapine-containing HAART. They were assessed for clinical and immunological response at the end of 24 and 48 weeks. Plasma nevirapine concentrations were measured at days 14, 28, 42 and 180 of starting HAART. Results 97 out of 114 (85.1%) patients were alive at the end of 48 weeks. The CD4 cell count showed a mean increase of 108 vs.113 cells/mm3 (p=0.83) at 24 weeks of HAART in cases and controls respectively. Overall, 58.73% patients in cases had viral loads of less than 400 copies/ml at the end of 48 weeks. The mean (± SD) Nevirapine concentrations of cases and control at 14, 28, 42 and 180 days were 2.19 ± 1.49 vs. 3.27 ± 4.95 (p = 0.10), 2.78 ± 1.60 vs. 3.67 ± 3.59 (p = 0.08), 3.06 ± 3.32 vs. 4.04 ± 2.55 (p = 0.10) respectively and 3.04 μg/ml (in cases). Conclusions Good immunological and clinical response can be obtained in HIV-TB co-infected patients receiving rifampicin and nevirapine concomitantly despite somewhat lower nevirapine trough concentrations. This suggests that rifampicin-containing ATT may be co administered in resource limited setting with nevirapine-containing HAART regimen without substantial reduction in antiretroviral effectiveness. Larger sample sized studies and longer follow-up are required to identify populations of individuals where the reduction in nevirapine concentration may result in lower ART response or shorter response duration

Climate Change and COP26: Are Digital Technologies and Information Management Part of the Problem or the Solution? An Editorial Reflection and Call to Action

The UN COP26 2021 conference on climate change offers the chance for world leaders to take action and make urgent and meaningful commitments to reducing emissions and limit global temperatures to 1.5 °C above pre-industrial levels by 2050. Whilst the political aspects and subsequent ramifications of these fundamental and critical decisions cannot be underestimated, there exists a technical perspective where digital and IS technology has a role to play in the monitoring of potential solutions, but also an integral element of climate change solutions. We explore these aspects in this editorial article, offering a comprehensive opinion based insight to a multitude of diverse viewpoints that look at the many challenges through a technology lens. It is widely recognized that technology in all its forms, is an important and integral element of the solution, but industry and wider society also view technology as being part of the problem. Increasingly, researchers are referencing the importance of responsible digitalization to eliminate the significant levels of e-waste. The reality is that technology is an integral component of the global efforts to get to net zero, however, its adoption requires pragmatic tradeoffs as we transition from current behaviors to a more climate friendly society